Drugs / iC9-GD2 T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01822652 | Aug 2013 → Dec 2015 overdue | neuroblastoma | Baylor College of Medicine | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iC9-GD2 T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01822652 ↗ |
| Action | Deplete | “we can put a new gene called a chimeric antigen receptor (CAR) into T cells that will make them recognize neuroblastoma cells and kill them” NCT01822652 ↗ |
| Modality | Cell therapy | “Autologous Activated T-Cells Transduced With A 3rd Generation GD-2 Chimeric Antigen Receptor And iCaspase9 Safety Switch” NCT01822652 ↗ |
| Route | Intravenous | “patients will be given an infusion of iC9 GD2 T cells into the vein through an IV line” NCT01822652 ↗ |